A Phase 1b/3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms MASTERKEY232
- Sponsors Amgen
- 23 Jul 2017 This trial has been restarted in Portugal.
- 19 Jul 2017 Planned End Date changed from 8 Nov 2022 to 4 Dec 2022.
- 19 Jul 2017 Planned primary completion date changed from 28 Jul 2021 to 23 Aug 2021.